Paula Trzepacz Net Worth

Paula Trzepacz biography

Dr. Paula T. Trzepacz is Executive Vice President and Chief Medical Officer of the Company. Prior to joining Neurotrope, Dr. Trzepacz was at Eli Lilly and Company for over 15 years where she was most recently a Senior Medical Fellow in Neurosciences drug development. She served on the global drug development team for Amyvid, the PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Prior to that, she led the Phase 2 medical team investigating mibampator, a novel AMPA receptor potentiator, for agitation and aggression in Alzheimer's disease patients. As Senior Medical Fellow on the global Strattera team for over three years Dr. Trzepacz was the medical lead for registration and regulatory related issues for its Attention Deficit Hyperactivity Disorder indications for both adult and pediatric populations, including design of new Phase 3 registration trials and collaborations with the European and Japanese Lilly teams. As Senior Medical Director of U.S. Neurosciences, she was responsible for a large medical team of physicians and other scientists including for the design and execution of many Phase 4 double-blind, randomized placebo-controlled clinical trials over a five year period. Some of those trials were used to support registration work in addition to answering key patient-relevant questions for practicing physicians. Importantly, the products her team supported included Prozac, Zyprexa, Cymbalta, and Strattera and their multiple indications, line extensions, and formulations.

What's Paula Trzepacz's mailing address?

Paula's mailing address filed with the SEC is 50 PARK PLACE, SUITE 1401, , NEWARK, NJ, 07102.

Insiders trading at NextTrip

Over the last 10 years, insiders at NextTrip have traded over $2,644 worth of NextTrip stock and bought 245,000 units worth $210,900 . The most active insiders traders include Bruce Bernstein, Ivan P. Gergel és Andrew D Perlman. On average, NextTrip executives and independent directors trade stock every 180 days with the average trade being worth of $69,913. The most recent stock trade was executed by Jonathan Schechter on 30 October 2020, trading 25,000 units of NTRP stock currently worth $24,500.

What does NextTrip do?

sigma labs, inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3d printing, and other advanced manufacturing technologies. sigma labs is pioneering the commercialization of in-process metallurgical and geometric quality assurance monitoring technology. printrite3d® with its software modules inspect™, contour™ and analytics™ is the industry's first, commercially available, platform independent, third party in-process quality monitoring system for metal additive manufacturing. it is available as a fully embedded oem installation or a stand-alone connection to your existing machines. additionally, sigma labs conducts contract metal 3d printing in materials inconnel718, 316 stainless, titanium, aluminum and ms1 tool steel. for more information please visit www.sigmalabsinc.com. for inquiries contact: sales@sigmalabsinc.com follow sigma labs on twi

NextTrip executives and stock owners

NextTrip executives and other stock owners filed with the SEC include:

• Robert Weinstein,
  Chief Financial Officer, Executive Vice President
• Jonathan Schechter,
  Director
• Kenneth Gorelick,
  Director
• Ivan Gergel,
  Director
• Bruce Bernstein,
  Director
• Paula Trzepacz,
  Executive Vice President and Chief Medical Officer
• William Singer,
  Vice Chairman of the Board
• Charles Ryan,
  Chief Executive Officer, Director
• Daniel Alkon,
  President, Chief Scientific Officer
• Joshua Silverman,
  Chairman of the Board
• Shana Phares,
  Director
• George Perry,
  Director
• Michael Ciraolo,
  COO and General Counsel
• Susanne Wilke,
  Director
• James Gottlieb,
  Director
• Andrew D Perlman,
  Director
• Warren W Wasiewski,
  
• Paul E. Freiman,
  See Remarks
• Charles S Ramat,
  President and CEO
• Larry Douglas Altstiel,
  Director
• Jay M Haft,
  Director
• John H Abeles,
  10% owner
• David Crockford,